Literature DB >> 33314654

Refining immunotherapeutic approaches to high-risk neuroblastoma based on tumor genomic profiles.

Liron D Grossmann1, John M Maris1.   

Abstract

In this issue, Coronado et al. attempt to improve our understanding of the factors affecting the response to immunotherapy in a large subset of high-risk neuroblastoma with hemizygous deletion of chromosome 11q. By using several computational approaches, the authors study potential transcriptional and post-transcriptional pathways that may affect the response to immunotherapy and further be leveraged therapeutically in a biomarker-directed fashion.
© 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

Entities:  

Keywords:  11q deletion; anti-GD2 therapy; immune checkpoint inhibition; microRNAs

Mesh：

Year:  2020        PMID： 33314654      PMCID： PMC7858281          DOI： 10.1002/1878-0261.12880

Source DB:  PubMed          Journal:  Mol Oncol        ISSN： 1574-7891            Impact factor:   7.449


  18 in total

1.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

Authors:  Alice L Yu; Andrew L Gilman; M Fevzi Ozkaynak; Wendy B London; Susan G Kreissman; Helen X Chen; Malcolm Smith; Barry Anderson; Judith G Villablanca; Katherine K Matthay; Hiro Shimada; Stephan A Grupp; Robert Seeger; C Patrick Reynolds; Allen Buxton; Ralph A Reisfeld; Steven D Gillies; Susan L Cohn; John M Maris; Paul M Sondel
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

2.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

3.  Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy.

Authors:  Teresa Davoli; Hajime Uno; Eric C Wooten; Stephen J Elledge
Journal:  Science       Date:  2017-01-20       Impact factor: 47.728

4.  Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN-Not-Amplified Human Neuroblastoma.

Authors:  Jun S Wei; Igor B Kuznetsov; Shile Zhang; Young K Song; Shahab Asgharzadeh; Sivasish Sindiri; Xinyu Wen; Rajesh Patidar; Sushma Najaraj; Ashley Walton; Jaime M Guidry Auvil; Daniela S Gerhard; Aysen Yuksel; Daniel Catchpoole; Stephen M Hewitt; Paul M Sondel; Robert Seeger; John M Maris; Javed Khan
Journal:  Clin Cancer Res       Date:  2018-05-21       Impact factor: 12.531

5.  Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.

Authors:  Kara L Davis; Elizabeth Fox; Melinda S Merchant; Joel M Reid; Rachel A Kudgus; Xiaowei Liu; Charles G Minard; Stephan Voss; Stacey L Berg; Brenda J Weigel; Crystal L Mackall
Journal:  Lancet Oncol       Date:  2020-03-17       Impact factor: 41.316

6.  Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study.

Authors:  Birgit Geoerger; C Michel Zwaan; Lynley V Marshall; Jean Michon; Franck Bourdeaut; Michela Casanova; Nadège Corradini; Gianluca Rossato; Mufiza Farid-Kapadia; Colby S Shemesh; Katherine E Hutchinson; Francis Donaldson; Minlei Liao; Hubert Caron; Tanya Trippett
Journal:  Lancet Oncol       Date:  2019-11-25       Impact factor: 41.316

7.  Multiple mechanisms disrupt the let-7 microRNA family in neuroblastoma.

Authors:  John T Powers; Kaloyan M Tsanov; Daniel S Pearson; Frederik Roels; Catherine S Spina; Richard Ebright; Marc Seligson; Yvanka de Soysa; Patrick Cahan; Jessica Theißen; Ho-Chou Tu; Areum Han; Kyle C Kurek; Grace S LaPier; Jihan K Osborne; Samantha J Ross; Marcella Cesana; James J Collins; Frank Berthold; George Q Daley
Journal:  Nature       Date:  2016-07-06       Impact factor: 49.962

Review 8.  11q deletion in neuroblastoma: a review of biological and clinical implications.

Authors:  Vid Mlakar; Simona Jurkovic Mlakar; Gonzalo Lopez; John M Maris; Marc Ansari; Fabienne Gumy-Pause
Journal:  Mol Cancer       Date:  2017-06-29       Impact factor: 27.401

9.  Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.

Authors:  Ruth Ladenstein; Ulrike Pötschger; Dominique Valteau-Couanet; Roberto Luksch; Victoria Castel; Isaac Yaniv; Genevieve Laureys; Penelope Brock; Jean Marie Michon; Cormac Owens; Toby Trahair; Godfrey Chi Fung Chan; Ellen Ruud; Henrik Schroeder; Maja Beck Popovic; Guenter Schreier; Hans Loibner; Peter Ambros; Keith Holmes; Maria Rita Castellani; Mark N Gaze; Alberto Garaventa; Andrew D J Pearson; Holger N Lode
Journal:  Lancet Oncol       Date:  2018-11-12       Impact factor: 41.316

10.  An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer.

Authors:  Marian L Burr; Christina E Sparbier; Kah Lok Chan; Yih-Chih Chan; Ariena Kersbergen; Enid Y N Lam; Elizabeth Azidis-Yates; Dane Vassiliadis; Charles C Bell; Omer Gilan; Susan Jackson; Lavinia Tan; Stephen Q Wong; Sebastian Hollizeck; Ewa M Michalak; Hannah V Siddle; Michael T McCabe; Rab K Prinjha; Glen R Guerra; Benjamin J Solomon; Shahneen Sandhu; Sarah-Jane Dawson; Paul A Beavis; Richard W Tothill; Carleen Cullinane; Paul J Lehner; Kate D Sutherland; Mark A Dawson
Journal:  Cancer Cell       Date:  2019-09-26       Impact factor: 31.743
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.